Shaping the Future of Infectious Diseases

"Patients are at the heart of what we do"

DAVID VEITCH, CEO

HCIM Genolier, March 31, 2026

Introducing Basilea and the executive management team

- Founded in 2000 as a spin off from Roche
- Profitable Swiss commercial-stage biopharmaceutical company
- About 190 employees
- Headquarters in Allschwil, Switzerland, in the Basel area life sciences hub
- Listed on the SIX Swiss Stock Exchange, Ticker: BSLN.SW

					
	DAVID VEITCH CEO	**ADESH KAUL** CFO	**MARC ENGELHARDT MD, PH.D** CMO	**GERRIT HAUCK PH.D.** CTO	**LAURENZ KELLENBERGER PH.D.** CSO
JOINED	2014	2009	2010	2018	2000
PREVIOUS ROLES	Bristol-Myers Squibb, SmithKline Beecham	POLYPHOR, Genedata	NOVARTIS, BRACCO	SANOFI	UNIVERSITY OF CAMBRIDGE, Roche

"Our experienced team brings deep expertise across Basilea's entire value chain."

Our focus is on identifying and generating commercial opportunities in the anti-infectives area

- We are focused on developing treatments for **severe bacterial** and **fungal diseases**
- Unmet medical needs:
  - Therapies with limited spectrum of activity
  - Growing resistance
  - Lack of oral dosing forms
  - Toxicities
- We strive to create sustainable value with meaningful benefits for patients and healthcare systems, generating long-term returns for investors and our partners
- Currently two revenue generating hospital anti-infective brands: Cresemba® and Zevtera®, and two phase 3 assets: fosmanogepix and ceftibuten-ledaborbactam

Manifestations of severe infections

***Candida* spp.**	Bloodstream, abdominal, osteoarticular, cardiac, ocular, CNS, pulmonary
***Aspergillus* spp.**	Pulmonary, sinuorbital, CNS, cardiac, cutaneous, abdominal
***Fusarium* spp.**	Bloodstream, cutaneous, sinuorbital, ocular, CNS, pulmonary
Mucorales fungi	Pulmonary, sinuorbital, CNS, renal, cutaneous, abdominal
Staphylococci	Bloodstream, cutaneous, cardiac, abdominal, osteoarticular, pulmonary
Enterobacteriaceae	Bloodstream, urinary, pulmonary, cutaneous, abdominal, osteoarticular
***Pseudomonas* spp.**	Bloodstream, urinary, pulmonary
Acinetobacter baumannii	Bloodstream, urinary, pulmonary, cutaneous

Business model

Unique capabilities, limited acquisition and development costs, commercialization partnerships supporting profitability

External pool of potential assets

In-license/acquire novel anti-infective assets

e.g. fosmanogepix and ceftibuten-ledaborbactam

Value-sharing financial structures with limited upfront and development milestone payments

Add value through clinical development

Upside: non-dilutive funds/support from governments and non-profit organizations

BARDA

CARB-X

File for regulatory approvals

Identify commercial partner

Manufacture/sell product through partnerships

Pfizer

AsahiKASEI

astellas

INNOVIVA Specialty Therapeutics

and more..

Lean and low risk commercialization model: limited selling expenses and no significant CAPEX

Eligible for royalties/ milestones from partners

Cashflow generating

Innovative anti-infective pipeline

Addressing urgent and evolving infection threats

Assets	Preclinical	Phase 1	Phase 2	Phase 3	Market
COMMERCIAL					
Cresemba® isavuconazole					
Invasive aspergillosis and mucormycosis (US, EU and several other countries)[1]					
Aspergillosis, (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan)					
Zevtera® ceftobiprole					
Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries)					
Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) (United States)					
PHASE 3					
Fosmanogepix					
Candidemia / invasive candidiasis (including *Candida auris*)					**USD ~1.0 bn** peak sales potential
Invasive mold infections (including invasive aspergillosis, fusariosis, lomentosporiosis, mucormycosis and other rare mold infections)					
Ceftibuten-ledaborbactam					
Complicated urinary tract infections (cUTI)					**USD ~500 mn** peak sales potential
PHASE 2 AND EARLIER					
BAL2062					
Invasive aspergillosis					
BAL2420 (LptA inhibitor)					
Severe Enterobacteriaceae infections					

[1] The registration status and approved indications may vary from country to country.

Cresemba® – Leading global antifungal brand by value

Differentiated by spectrum, safety and tolerability

Global commercial partnerships

Marketed in **76** countries

United States	astellas
Canada	AVIR PHARMA
Latin America	Knight
Europe (excluding Nordics)	Pfizer
Nordics	UNIMEDIC PHARMA
MENA Region	hikma.
Asia-Pacific and China	Pfizer
Japan	AsahiKASEI

In-market sales

USD **693** million
October 2024 to September 2025

27%
Year-on-Year growth



Zevtera® – Broad-spectrum hospital anti-MRSA cephalosporin

- Single agent first-line bactericidal therapy with proven efficacy in SAB, ABSSSI, HABP and CABP
- Strong activity against MSSA and MRSA with robust Gram-negative coverage
- Low propensity for resistance development and safety profile consistent with the cephalosporin class[1, 2, 3, 4]
- Launched in the US in July 2025 by Innoviva Specialty Therapeutics; commercialized also in China, selected countries in Europe, the MENA-region and Canada

US launch progressing well, with initial positive clinical experience

- Important hospital formulary wins
- Reimbursement: NTAP designation, Medicaid and 340B pricing, and J-code for outpatient billing
- Repeat orders from major hospitals
- US market exclusivity until April 2034

US opportunity –

From the Daptomycin regional sales
(2015, before LOE)[5]



[1] LSyed YY. Drugs. 2014;74:1523-1542 and Basilea data on file. [2] Overcash JS et al. Clin Infect Dis. 2021;73:e1507-e1517. [3] Holland TL et al. N Engl J Med 2023;389:1390-1401. [4] Rubino CM et al. Pediatr Infect Dis J. 2021;40:997-1003. [5] Source: IQVIA Analytics Link, September 2025.
MRSA: Methicillin-resistant *Staphylococcus aureus*. MSSA: Methicillin-susceptible *Staphylococcus aureus*.
LOE: Loss of exclusivity; ROW: Rest Of World; NTAP: New Technology Add-On Payment

Financials & Outlook

Strong financial results FY 2025 – Surpassed financial guidance

in CHF million	FY 2024	FY 2025A	(FY 2025 guidance)
Cresemba and Zevtera related revenue	**194.8**	**194.4**	(190)
of which royalty income	*96.7*	*111.6*	*(110)*
of which milestone and upfront payments	*40.4*	*32.0*	
Other revenue	13.7	38.0	(35)
Total revenue	**208.5**	**232.4**	(225)
Cost of products sold	38.7	39.3	
Operating expenses	108.7	141.5	
Operating profit	**61.2**	**51.5**	(50)
Net profit	**77.6**	**40.2**	
Cash and cash equivalents and restricted cash	**124.6**	**162.3**	
Convertible senior unsecured bonds	95.9	75.4	
Net cash (as of December 31, 2024/2025)	**28.6**	**86.9**	

2025: including CHF 12 mn upfront and milestone expenses for in-licensing ceftibuten-ledaborbactam

2024: including CHF 17.3 mn deferred tax asset benefit recognition

Note: Consolidated figures in conformity with US GAAP; rounding applied consistently

FY 2026 financial guidance – Increasing revenue and operating profit while progressing the R&D portfolio

in CHF million	FY 2026 (guidance)	FY 2025 (actuals)
Cresemba and Zevtera related revenue	~200	194.4
of which royalty income	*~120*	*111.6*
Total revenue	**~ 10% increase**	**232.4**
Research and development expenses	~ 20% increase	105.9
Operating profit	**~ 20% increase**	**51.5**

Note: Consistent rounding was applied.

Commercial portfolio outlook beyond 2026

Current phase 3 pipeline has the potential to double 2025 in-market sales



“Agenda 2030” – Basilea well positioned for sustainable growth

Strong financial position:

- Approx. CHF 160 million cash as of end-2025
- Approx. CHF 600 million cumulative cash flow from Cresemba and Zevtera from 2026 to 2030
- Up to USD 330 million potential additional non-dilutive funding from existing agreements

This allows us to:

- Bring phase 3 programs to market with the potential to double current in-market sales
- Advance early-stage pipeline
- In-license or acquire exciting new assets

Potential upsides:

- Later than expected Cresemba generic entry in the US and Europe
- New non-dilutive funding agreements
- First revenues from fosmanogepix and ceftibuten-ledaborbactam

Five reasons to invest in Basilea today

1 Profitable commercial-stage company with two marketed anti-infective products

2 Strong financial position with sustainable cash flows supporting continued growth

3 Leading strategic position in an area of high-value unmet medical need, addressing rising challenges in treating severe bacterial and fungal infections

4 Phase 3 programs alone create opportunity to double 2025 in-market sales

5 Proven, capital-efficient business model with low operational expenses, non-dilutive funding, and strong global partnerships

Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.

Shaping the Future
of Infectious Diseases

Hegenheimermattweg 167b
4123 Allschwil
Switzerland

info@basilea.com
www.basilea.com